Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Cao, Maria D ^a,e   Giskeødegård, Guro F ^a   Bathen, Tone F ^a,b   Sitter, Beathe ^a,b   Bofin, Anna ^a   Lønning, Per E ^c,d   Lundgren, Steinar ^a,b   Gribbestad, Ingrid S ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF BERGEN   (Norway)

^e NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE DERIVATIVE; EPIRUBICIN; GLUCOSE; GLYCINE; LACTIC ACID; PACLITAXEL;

ACCURACY; ADJUVANT THERAPY; ADULT; ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER TISSUE; CLINICAL CLASSIFICATION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG MONITORING; EX VIVO STUDY; HUMAN; HUMAN TISSUE; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PROTON NUCLEAR MAGNETIC RESONANCE; RANDOMIZED CONTROLLED TRIAL; SURVIVAL PREDICTION; SURVIVAL TIME; TISSUE LEVEL; TISSUE METABOLISM; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; EPIRUBICIN; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; PACLITAXEL; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84856091199     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-39     Document Type: Article

References (52)

1. Mathew J, Asgeirsson KS, Cheung KL, Chan S, Dahda A, Robertson JF. Neoadjuvant chemotherapy for locally advanced breast cancer: a review of the literature and future directions. Eur J Surg Oncol 2009, 35(2):113-122. 10.1016/j.ejso.2008.03.015, 18502088.
2. Makhoul I, Kiwan E. Neoadjuvant systemic treatment of breast cancer. J Surg Oncol 2011, 103(4):348-357. 10.1002/jso.21696, 21337570.
3. Makris A, Powles TJ, Ashley SE, Chang J, Hickish T, Tidy VA, Nash AG, Ford HT. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol 1998, 9(11):1179-1184. 10.1023/A:1008400706949, 9862047.
4. Kong X, Moran MS, Zhang N, Haffty B, Yang Q. Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients. Eur J Cancer 2011, Corrected Proof.
5. Ackerstaff E, Glunde K, Bhujwalla ZM. Choline phospholipid metabolism: a target in cancer cells?. J Cell Biochem 2003, 90(3):525-533. 10.1002/jcb.10659, 14523987.
6. Katz-Brull R, Lavin PT, Lenkinski RE. Clinical utility of proton magnetic resonance spectroscopy in characterizing breast lesions. J Natl Cancer Inst 2002, 94(16):1197-1203. 10.1093/jnci/94.16.1197, 12189222.
7. Baek H-M, Chen J-H, Nalcioglu O, Su M-Y. Proton MR spectroscopy for monitoring early treatment response of breast cancer to neo-adjuvant chemotherapy. Ann Oncol 2008, 19(5):1022-1024. 10.1093/annonc/mdn121, 2613189, 18372283.
8. Jagannathan NR, Kumar M, Seenu V, Coshic O, Dwivedi SN, Julka PK, Srivastava A, Rath GK. Evaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer. Br J Cancer 2001, 84(8):1016-1022. 10.1054/bjoc.2000.1711, 2363867, 11308247.
9. Cheng LL, Chang IW, Smith BL, Gonzalez RG. Evaluating human breast ductal carcinomas with high-resolution magic-angle spinning proton magnetic resonance spectroscopy. J Magn Reson 1998, 135(1):194-202. 10.1006/jmre.1998.1578, 9799694.
10. Tessem MB, Swanson MG, Keshari KR, Albers MJ, Joun D, Tabatabai ZL, Simko JP, Shinohara K, Nelson SJ, Vigneron DB, Gribbestad IS, Kurhanewicz J. Evaluation of lactate and alanine as metabolic biomarkers of prostate cancer using 1H HR-MAS spectroscopy of biopsy tissues. Magn Reson Med 2008, 60(3):510-516. 10.1002/mrm.21694, 2613807, 18727052.
11. Sitter B, Sonnewald U, Spraul M, Fjosne HE, Gribbestad IS. High-resolution magic angle spinning MRS of breast cancer tissue. NMR Biomed 2002, 15(5):327-337. 10.1002/nbm.775, 12203224.
12. Bathen TF, Jensen LR, Sitter B, Fjosne HE, Halgunset J, Axelson DE, Gribbestad IS, Lundgren S. MR-determined metabolic phenotype of breast cancer in prediction of lymphatic spread, grade, and hormone status. Breast Cancer Res Treat 2007, 104(2):181-189. 10.1007/s10549-006-9400-z, 17061040.
13. Giskeødegård GF, Grinde MT, Sitter B, Axelson DE, Lundgren S, Fjøsne HE, Dahl S, Gribbestad IS, Bathen TF. Multivariate modeling and prediction of breast cancer prognostic factors using MR metabolomics. J Proteome Res 2010, 9(2):972-979. 10.1021/pr9008783, 19994911.
14. Sitter B, Lundgren S, Bathen TF, Halgunset J, Fjosne HE, Gribbestad IS. Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters. NMR Biomed 2006, 19(1):30-40. 10.1002/nbm.992, 16229059.
15. Cao MD, Sitter B, Bathen TF, Bofin A, Lonning PE, Lundgren S, Gribbestad IS. Predicting long-term survival and treatment response in breast cancer patients receiving neoadjuvant chemotherapy by MR metabolic profiling. NMR Biomed 2012, 25(2):369-378. doi: 10.1002/nbm.1762. Epub 2011 Aug 8, 10.1002/nbm.1762, 21823183.
16. Chrisanthar R, Knappskog S, Løkkevik E, Anker G, Østenstad B, Lundgren S, Risberg T, Mjaaland I, Skjønsberg G, Aas T, Schlichting E, Fjösne HE, Nysted A, Lillehaug JR, Lønning PE. Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with Epirubicin or Paclitaxel. PLoS ONE 2011, 6(4):e19249. 10.1371/journal.pone.0019249, 3083424, 21556366.
17. Hayward JL, Carbone PP, Heuson JC, Kumaoka S, Segaloff A, Rubens RD. Assessment of response to therapy in advanced breast cancer. Cancer 1977, 39(3):1289-1294. 10.1002/1097-0142(197703)39:3<1289::AID-CNCR2820390340>3.0.CO;2-F, 912660.
18. Eilers PHC. Parametric Time Warping. Anal Chem 2004, 76:404-411. 10.1021/ac034800e, 14719890.
19. Savorani F, Tomasi G, Engelsen SB. icoshift: a versatile tool for the rapid alignment of 1D NMR spectra. J Magn Reson 2010, 202(2):190-202. 10.1016/j.jmr.2009.11.012, 20004603.
20. Wold S, Sjöström M, Eriksson L. PLS-regression: a basic tool of chemometrics. Chemometrics Intell Lab Syst 2001, 58(2):109-130.
21. Chong I-G, Jun C-H. Performance of some variable selection methods when multicollinearity is present. Chemometrics Intell Lab Syst 2005, 78(1-2):103-112.
22. Chen J, Wang W, Lv S, Yin P, Zhao X, Lu X, Zhang F, Xu G. Metabonomics study of liver cancer based on ultra performance liquid chromatography coupled to mass spectrometry with HILIC and RPLC separations. Anal Chim Acta 2009, 650(1):3-9. 10.1016/j.aca.2009.03.039, 19720165.
23. Westerhuis J, Hoefsloot H, Smit S, Vis D, Smilde A, van Velzen E, van Duijnhoven J, van Dorsten F. Assessment of PLSDA cross validation. Metabolomics 2008, 4(1):81-89.
24. van Velzen EJJ, Westerhuis JA, van Duynhoven JPM, van Dorsten FA, Hoefsloot HCJ, Jacobs DM, Smit S, Draijer R, Kroner CI, Smilde AK. Multilevel data analysis of a crossover designed human nutritional intervention study. J Proteome Res 2008, 7(10):4483-4491. 10.1021/pr800145j, 18754629.
25. Westerhuis JA, van Velzen EJ, Hoefsloot HC, Smilde AK. Multivariate paired data analysis: multilevel PLSDA versus OPLSDA. Metabolomics 2010, 6(1):119-128. 10.1007/s11306-009-0185-z, 2834771, 20339442.
26. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004, 56(2):185-229. 10.1124/pr.56.2.6, 15169927.
27. McGrogan BT, Gilmartin B, Carney DN, McCann A. Taxanes, microtubules and chemoresistant breast cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2008, 1785(2):96-132.
28. Brizel DM, Schroeder T, Scher RL, Walenta S, Clough RW, Dewhirst MW, Mueller-Klieser W. Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001, 51(2):349-353. 10.1016/S0360-3016(01)01630-3, 11567808.
29. Walenta S, Wetterling M, Lehrke M, Schwickert G, Sundfør K, Rofstad EK, Mueller-Klieser W. High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Res 2000, 60(4):916-921.
30. Quennet V, Yaromina A, Zips D, Rosner A, Walenta S, Baumann M, Mueller-Klieser W. Tumor lactate content predicts for response to fractionated irradiation of human squamous cell carcinomas in nude mice. Radiother Oncol 2006, 81(2):130-135. 10.1016/j.radonc.2006.08.012, 16973228.
31. Hanahan D, Weinberg Robert A. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674. 10.1016/j.cell.2011.02.013, 21376230.
32. Locasale J, Cantley L. Altered metabolism in cancer. BMC Biology 2010, 8(1):88. 2892450, 20598111.
33. Brown N, Bicknell R. Hypoxia and oxidative stress in breast cancer: oxidative stress--its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Res 2001, 3(5):323-327. 10.1186/bcr315, 138696, 11597322.
34. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324(5930):1029-1033. 10.1126/science.1160809, 2849637, 19460998.
35. Duffy M, Maguire T, Hill A, McDermott E, O'Higgins N. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2000, 2:252-257. 10.1186/bcr65, 138784, 11250717.
36. Mathupala S, Colen C, Parajuli P, Sloan A. Lactate and malignant tumors: a therapeutic target at the end stage of glycolysis. J Bioenerg Biomembr 2007, 39(1):73-77. 10.1007/s10863-006-9062-x, 17354062.
37. Weidemann A, Johnson RS. Biology of HIF-1alpha. Cell Death Differ 2008, 15(4):621-627. 10.1038/cdd.2008.12, 18259201.
38. Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 2006, 9(6):425-434. 10.1016/j.ccr.2006.04.023, 16766262.
39. Duch J, Fuster D, Muñoz M, Fernández P, Paredes P, Fontanillas M, Guzmán F, Rubí S, Lomeña F, Pons F. 18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer. European Journal of Nuclear Medicine and Molecular Imaging 2009, 36(10):1551-1557. 10.1007/s00259-009-1116-y, 19326117.
40. Rousseau C, Devillers A, Sagan C, Ferrer L, Bridji B, Campion L, Ricaud M, Bourbouloux E, Doutriaux I, Clouet M, Berton-Rigaud D, Bouriel C, Delecroix V, Garin E, Rouquette S, Resche I, Kerbrat P, Chatal JF, Campone M. Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]Fluorodeoxyglucose positron emission tomography. J Clin Oncol 2006, 24(34):5366-5372. 10.1200/JCO.2006.05.7406, 17088570.
41. Davies NP, Wilson M, Natarajan K, Sun Y, MacPherson L, Brundler MA, Arvanitis TN, Grundy RG, Peet AC. Non-invasive detection of glycine as a biomarker of malignancy in childhood brain tumours using in-vivo1H MRS at 1.5 Tesla confirmed by ex-vivo high-resolution magic-angle spinning NMR. NMR Biomed 2010, 23(1):80-87. 10.1002/nbm.1432, 19795380.
42. Righi V, Andronesi OC, Mintzopoulos D, Black PM, Tzika AA. High-resolution magic angle spinning magnetic resonance spectroscopy detects glycine as a biomarker in brain tumors. Int J Oncol 2010, 36(2):301-306.
43. Moestue S, Borgan E, Huuse E, Lindholm E, Sitter B, Børresen-Dale A, Engebraaten O, Mælandsmo G, Gribbestad I. Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models. BMC cancer 2010, 10(1):433. 10.1186/1471-2407-10-433, 2931488, 20716336.
44. Sitter B, Bathen TF, Singstad TE, Fjøsne HE, Lundgren S, Halgunset J, Gribbestad IS. Quantification of metabolites in breast cancer patients with different clinical prognosis using HR MAS MR spectroscopy. NMR Biomed 2010, 23(4):424-431.
45. Aboagye EO, Bhujwalla ZM. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res 1999, 59(1):80-84.
46. Ronen SM, Jackson LE, Beloueche M, Leach MO. Magnetic resonance detects changes in phosphocholine associated with Ras activation and inhibition in NIH 3 T3 cells. Br J Cancer 2001, 84(5):691-696. 10.1054/bjoc.2000.1663, 2363797, 11237392.
47. Baek H-M, Yu HJ, Chen J-H, Nalcioglu O, Su M-Y. Quantitative correlation between 1H MRS and dynamic contrast-enhanced MRI of human breast cancer. Magn Reson Imaging 2008, 26(4):523-531. 10.1016/j.mri.2007.10.002, 2653063, 18060716.
48. Chen JH, Mehta RS, Baek HM, Nie K, Liu H, Lin MQ, Yu HJ, Nalcioglu O, Su MY. Clinical characteristics and biomarkers of breast cancer associated with choline concentration measured by 1H MRS. NMR Biomed 2011, 24(3):316-324. 10.1002/nbm.1595, 3075960, 20862660.
49. Glunde K, Shah T, Winnard PT, Raman V, Takagi T, Vesuna F, Artemov D, Bhujwalla ZM. Hypoxia regulates choline kinase expression through Hypoxia-Inducible Factor-1α signaling in a human prostate cancer model. Cancer Res 2008, 68(1):172-180. 10.1158/0008-5472.CAN-07-2678, 18172309.
50. de Molina AR, Báñez-Coronel M, Gutiérrez R, Rodríguez-González A, Olmeda D, Megías D, Lacal JC. Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression. Cancer Res 2004, 64(18):6732-6739. 10.1158/0008-5472.CAN-04-0489, 15374991.
51. Shah T, Wildes F, Penet M-F, Winnard PT, Glunde K, Artemov D, Ackerstaff E, Gimi B, Kakkad S, Raman V, Bhujwalla ZM. Choline kinase overexpression increases invasiveness and drug resistance of human breast cancer cells. NMR Biomed 2010, 23(6):633-642. 10.1002/nbm.1510, 3115627, 20623626.
52. Jordan K, He W, Halpern E, Wu C, Cheng L. Evaluation of tissue metabolites with high resolution magic angle spinning MR spectroscopy human prostate samples after three-year storage at -80°C. Biomarker Insights 2007, 2:147. 2717844, 19662199.